TC Biopharm () (TCBP)
0.50
0.00 (0.00%)
At close: Mar 21, 2025, 3:59 PM
0.50
0.00%
After-hours: Mar 21, 2025, 04:00 PM EDT
0.00% (1D)
| Bid | n/a |
| Market Cap | 256.5K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.57M |
| EPS (ttm) | -4794.42 |
| PE Ratio (ttm) | -0.00010428790135198835 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | n/a |
| Volume | 5,896,474 |
| Avg. Volume (20D) | 377,721 |
| Open | 1.51 |
| Previous Close | 0.50 |
| Day's Range | 0.50 - 1.51 |
| 52-Week Range | 0.08 - 523.20 |
| Beta | 0.01 |
About TCBP
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom....
Industry Biotechnology
Sector Healthcare
IPO Date Feb 11, 2022
Employees 41
Stock Exchange NASDAQ
Ticker Symbol TCBP
Website https://www.tcbiopharm.com
Analyst Forecast
According to 1 analyst ratings, the average rating for TCBP stock is "Buy." The 12-month stock price forecast is $48, which is an increase of 9500.00% from the latest price.
Stock Forecasts1 month ago
-67.53%
TC BioPharm shares are trading lower after the com...
Unlock content with
Pro Subscription
2 months ago
-30.14%
TC BioPharm shares are trading lower after the company announced a change in its ADS ratio from representing 200 ordinary shares to 4,000.
